The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
September 14th 2024
Tumor infiltrating lymphocytes may have prognostic utility for OS outcomes with adjuvant chemotherapy and trastuzumab in early HER2-positive breast cancer.
Dr. Chien on De-Escalation Strategies for Patients With HER2-Positive Breast Cancer
October 27th 2018A. Jo Chien, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses de-escalation strategies for patients with HER2-positive breast cancer.
Dr. Gradishar on Personalized Treatment in Breast Cancer
October 17th 2018William J. Gradishar, MD, chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the rise of personalized treatment in breast cancer.
Adjuvant T-DM1 Improves iDFS in Phase III HER2+ Breast Cancer Trial
October 15th 2018Ado-trastuzumab emtansine (T-DM1; Kadcyla) was found to significantly reduce the risk of disease recurrence or death compared with trastuzumab (Herceptin) as an adjuvant treatment in patients with HER2-positive early breast cancer who have residual disease following neoadjuvant therapy.
Dr. Hurvitz on Novel Agents in HER2-Positive Breast Cancer
October 10th 2018Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses novel agents in HER2-positive breast cancer.
Dr. Formenti on Recent Progress With HER2-Targeted Therapy
October 2nd 2018Silvia Chiara Formenti, MD, chair, Department of Radiation Oncology, Weill Cornell, associate director, Meyer Cancer Center, radiation oncologist-in-chief, NewYork-Presbyterian Hospital, discusses the recent progress with HER2-targeted therapy in the treatment of breast cancer.
Regimen Could Reduce Cardiotoxicity in HER2+ Breast Cancer
Women with operable HER2-positive breast cancer had similar long-term survival outcomes with either concurrent or sequential chemotherapy in the neoadjuvant setting, according to newly published results from the phase III ACOSOG Z1041 trial.
Dr. Kalinsky on CNS Involvement in HER2+ Breast Cancer
September 20th 2018Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses central nervous system involvement in HER2-positive breast cancer.
Dr. Hurvitz on HER2-Targeted Therapies in Breast Cancer
September 13th 2018Sara Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses HER2-targeted therapies for the treatment of breast cancer.
Dr. Murthy on De-Escalation Strategies in HER2-Positive Breast Cancer
September 6th 2018Rashmi K. Murthy, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses de-escalation strategies for patients with HER2-positive breast cancer.
Dr. Kalinsky Discusses the Evolution of HER2+ Breast Cancer
September 5th 2018Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the evolution of treatment for patients with HER2-positive metastatic breast cancer.
Dr. Tolaney Discusses the Role of Chemotherapy in HER2+ Breast Cancer
August 22nd 2018Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the role of chemotherapy in the treatment of patients with HER2-positive breast cancer.
New Recommendations Improve Accuracy of HER2 Status Designation
The guidelines for establishing HER2 status for patients with breast cancer with unclear results on initial testing have been finetuned in an update that the American Society of Clinical Oncology and the College of American Pathologists recently issued.
Dr. Hurvitz on How to Navigate HER2-Targeted Therapy in Breast Cancer
August 10th 2018Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, advises how to navigate therapy for patients with HER2-positive breast cancer.
Dr. Kalinsky on Neratinib and Tucatinib in HER2+ Metastatic Breast Cancer
August 8th 2018Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical School, discusses the potential of neratinib (Nerlynx) and tucatinib in HER2-positive metastatic breast cancer.
Dr. Shafaee on the PERSEPHONE Trial in Early-Stage HER2+ Breast Cancer
July 19th 2018Maryam Nemati Shafaee, MD, assistant professor, Duncan Cancer Center, Lester & Sue Smith Breast Cancer, Baylor College of Medicine, discusses the PERSEPHONE trial in women with early-stage HER2-positive breast cancer.